ADRB1andADBR2Gene Polymorphisms and the Ocular Hypotensive Response to Topical Betaxolol in Healthy Mexican Subjects
Authors:
- Guillermo Pacheco CuellarGCGuillermo Pacheco Cuellar
- Jaime Toral-LópezJTJaime Toral-López
- Silvia Fanny Lara HuertaSHSilvia Fanny Lara Huerta
- Luz María Gonzalez-HuertaLGLuz María Gonzalez-Huerta
- Héctor Urueta-CuellarHUHéctor Urueta-Cuellar
- Ma Refugio Rivera-VegaMRMa Refugio Rivera-Vega
- Ignacio Babayan-MenaIBIgnacio Babayan-Mena
- Sergio A. Cuevas-CovarrubiasSCSergio A. Cuevas-Covarrubias
- 21 April 2014
- journal article
- Published by Taylor & Francis in Current Eye Research
- Vol. 39 (11) , 1076-1080
Abstract
Background: The β adrenergic receptors (ADRB) are expressed in the ciliary body and trabecular meshwork, structures involved in aqueous humor production and outflow, respectively. ADRB are members of the adrenergic family of G-protein-coupled receptors. Topic β blockers have a good local and systemic tolerance; they reduce the aqueous humor production and eye strain blocking the ADRB of the ciliary body and interfering with adenylate cyclase. However, the ocular hypotensive response is not the same in all patients and could be mediated by the polymorphisms of the ADRB genes. Materials and methods: Seventy-two healthy subjects were studied after treatment with topical betaxolol in both eyes. We analyzed ADRB1 and ADRB2 gene polymorphisms by PCR and automated DNA sequencing. Results: There was statistically significant difference between baseline intraocular pressure (IOP) and final IOP of both eyes (baseline IOP 16.2 ± 1.2 – follow-up IOP 13.6 ± 2.0 (mean difference–2.5 ± 1.3, p < 0.001). Gly389 had a higher baseline IOP than Arg389 (17.0 ± 1.2 mmHg versus 16.0 ± 1.2 mmHg; p = 0.02), and conversely Arg389 had a greater magnitude of response than Gly389 to betaxolol therapy (−2.9 ± 1.1 mmHg versus −0.7 ± 0.4 mmHg; p < 0.001). Gln27 had a higher response than Glu27 (−2.7 ± 1.3 mmHg versus −1.9 ± 1.0; p = 0.02). Conclusion: Arg389 polymorphism of the ADRB1 gene and Gln27 polymorphism of the ADRB2 gene were associated with the hypotensive response to topic betaxolol in healthy Mexican volunteers.Keywords
This publication has 16 references indexed in Scilit:
- Pharmacogenetics of Ophthalmic Topical β-BlockersPersonalized Medicine, 2008
- Medical Management of GlaucomaInternational Ophthalmology Clinics, 2008
- Beta blocker specificity: a building block toward personalized medicineJournal of Clinical Investigation, 2007
- β1-Adrenergic Receptor Polymorphisms and Clinical Efficacy of Betaxolol Hydrochloride in Normal VolunteersOphthalmology, 2005
- The selectivity of β‐adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptorsBritish Journal of Pharmacology, 2005
- The Comparative Cardiovascular, Pulmonary, Ocular Blood Flow, and Ocular Hypotensive Effects of Topical Travoprost, Bimatoprost, Brimonidine, and BetaxololJournal of Ocular Pharmacology and Therapeutics, 2004
- Are there any benefits of Betoptic ® S (betaxolol HCl ophthalmic suspension) over other β-blockers in the treatment of glaucoma?Expert Opinion on Pharmacotherapy, 2004
- What Is the Role of β-Adrenergic Signaling in Heart Failure?Circulation Research, 2003
- Polymorphism in the β 1 -Adrenergic Receptor Gene and HypertensionCirculation, 2001
- A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic ReceptorJournal of Biological Chemistry, 1999